Advancement in the 1L Treatment of Unresectable or Metastatic HCC

Description

Supported by: Genentech, A Member of the Roche Group

This program will provide an overview of HCC disease and staging, IMbrave150 including the clinical trial design, patient characteristics, pivotal efficacy and safety data, and exploratory subgroup analyses on patients’ risk status, as well as Genentech patient support information.

Presenter:

Victor Ankoma-Sey, MD, MD FACP, FAASLD